Trending NewsTrending NewsTop-Rated StocksTop-RatedNASDAQ:PTGX Protagonist Therapeutics (PTGX) Stock Price, News & Analysis $62.14 +2.92 (+4.93%) Closing price 09/18/2025 04:00 PM EasternExtended Trading$62.16 +0.02 (+0.02%) As of 09/18/2025 06:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Protagonist Therapeutics Stock (NASDAQ:PTGX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get PTGX alerts:Sign Up Key Stats Today's Range$58.91▼$62.2150-Day Range$50.96▼$62.1452-Week Range$33.31▼$62.21Volume1.36 million shsAverage Volume920,566 shsMarket Capitalization$3.87 billionP/E Ratio88.77Dividend YieldN/APrice Target$68.08Consensus RatingBuy Company Overview Protagonist Therapeutics, Inc. (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care. Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease. PTG-200, a selective interleukin-23 receptor antagonist, is in Phase 2 clinical trials for moderate to severe Crohn’s disease. The company’s PTG-300 program is a hepcidin mimetic being evaluated in hematologic disorders characterized by iron overload, including polycythemia vera and myelofibrosis. Founded in 2006 and headquartered in San Diego, California, Protagonist Therapeutics conducts global clinical trials across North America, Europe and Asia. The company is led by a team of seasoned biotechnology executives with deep expertise in peptide drug discovery and development. Protagonist maintains collaborations with academic institutions and industry partners to advance its pipeline and explore additional therapeutic areas where oral peptide therapeutics may deliver significant patient benefit.AI Generated. May Contain Errors. Read More Protagonist Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks42nd Percentile Overall ScorePTGX MarketRank™: Protagonist Therapeutics scored higher than 42% of companies evaluated by MarketBeat, and ranked 699th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingBuy Consensus RatingProtagonist Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.08, and is based on 9 buy ratings, 1 hold rating, and no sell ratings.Upside/DownsideThe consensus price target for Protagonist Therapeutics is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageProtagonist Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Protagonist Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Protagonist Therapeutics are expected to decrease in the coming year, from $2.43 to ($0.64) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Protagonist Therapeutics is 88.77, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 281.45.Price to Earnings Ratio vs. SectorThe P/E ratio of Protagonist Therapeutics is 88.77, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 76.86.Price to Book Value per Share RatioProtagonist Therapeutics has a P/B Ratio of 5.48. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Protagonist Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted11.58% of the float of Protagonist Therapeutics has been sold short.Short Interest Ratio / Days to CoverProtagonist Therapeutics has a short interest ratio ("days to cover") of 8.2.Change versus previous monthShort interest in Protagonist Therapeutics has recently increased by 8.56%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldProtagonist Therapeutics does not currently pay a dividend.Dividend GrowthProtagonist Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted11.58% of the float of Protagonist Therapeutics has been sold short.Short Interest Ratio / Days to CoverProtagonist Therapeutics has a short interest ratio ("days to cover") of 8.2.Change versus previous monthShort interest in Protagonist Therapeutics has recently increased by 8.56%, indicating that investor sentiment is decreasing significantly. News and Social Media2.6 / 5News Sentiment0.76 News SentimentProtagonist Therapeutics has a news sentiment score of 0.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.63 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 33 news articles for Protagonist Therapeutics this week, compared to 7 articles on an average week. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Protagonist Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,687,577.00 in company stock.Percentage Held by InsidersOnly 4.90% of the stock of Protagonist Therapeutics is held by insiders.Percentage Held by Institutions98.63% of the stock of Protagonist Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Protagonist Therapeutics' insider trading history. Receive PTGX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Protagonist Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PTGX Stock News HeadlinesProtagonist Therapeutics (NASDAQ:PTGX) Director Sells $237,000.00 in StockAugust 30, 2025 | insidertrades.comProtagonist Therapeutics (NASDAQ:PTGX) Receives "Buy" Rating from HC WainwrightSeptember 18 at 4:11 AM | americanbankingnews.comAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking and savings account… With this better, more technologically advanced dollar. President Trump himself called it a "big innovation"… And said that this new form of currency represents "American brilliance at its best." | Brownstone Research (Ad)Barclays Initiates Coverage of Protagonist Therapeutics (PTGX) with Overweight RecommendationSeptember 17 at 6:28 PM | msn.comDemystifying Protagonist Therapeutics: Insights From 4 Analyst ReviewsSeptember 17 at 6:28 PM | benzinga.comProtagonist Therapeutics, Inc. (PTGX): A Bull Case TheorySeptember 17 at 6:28 PM | msn.comProtagonist Therapeutics, Inc. (PTGX): A Bull Case Theory September 17 at 12:31 PM | insidermonkey.comBarclays backs biotech with fresh calls on oncology and immunology stocksSeptember 17 at 5:18 AM | investing.comSee More Headlines PTGX Stock Analysis - Frequently Asked Questions How have PTGX shares performed this year? Protagonist Therapeutics' stock was trading at $38.60 at the beginning of 2025. Since then, PTGX stock has increased by 61.0% and is now trading at $62.14. How were Protagonist Therapeutics' earnings last quarter? Protagonist Therapeutics, Inc. (NASDAQ:PTGX) released its quarterly earnings results on Wednesday, August, 6th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.53) by $0.02. The firm earned $5.55 million during the quarter, compared to the consensus estimate of $8.32 million. Protagonist Therapeutics had a net margin of 24.88% and a trailing twelve-month return on equity of 8.12%. When did Protagonist Therapeutics IPO? Protagonist Therapeutics (PTGX) raised $70 million in an IPO on Thursday, August 11th 2016. The company issued 5,800,000 shares at a price of $11.00-$13.00 per share. Leerink Partners, Barclays and BMO Capital Markets served as the underwriters for the IPO. Who are Protagonist Therapeutics' major shareholders? Top institutional shareholders of Protagonist Therapeutics include BVF Inc. IL (5.16%), State Street Corp (5.16%), Geode Capital Management LLC (2.33%) and Adage Capital Partners GP L.L.C. (1.76%). Insiders that own company stock include Dinesh V Ph D Patel, Suneel Gupta, Arturo Md Molina, Asif Ali and William D Waddill. View institutional ownership trends. How do I buy shares of Protagonist Therapeutics? Shares of PTGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Protagonist Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Protagonist Therapeutics investors own include Voyager Therapeutics (VYGR), American Water Works (AWK), The RMR Group (RMR), Waste Connections (WCN), DiamondRock Hospitality (DRH), iShares Micro-Cap ETF (IWC) and AU Optronics (AUOTY). Company Calendar Last Earnings8/06/2025Today9/18/2025Next Earnings (Estimated)11/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PTGX CIK1377121 Webwww.protagonist-inc.com Phone(510) 474-0170FaxN/AEmployees120Year Founded2006Price Target and Rating Average Price Target for Protagonist Therapeutics$68.08 High Price Target$80.00 Low Price Target$38.00 Potential Upside/Downside+9.6%Consensus RatingBuy Rating Score (0-4)3.08 Research Coverage12 Analysts Profitability EPS (Trailing Twelve Months)$0.70 Trailing P/E Ratio88.77 Forward P/E Ratio25.57 P/E GrowthN/ANet Income$275.19 million Net Margins24.88% Pretax Margin25.71% Return on Equity8.12% Return on Assets7.41% Debt Debt-to-Equity RatioN/A Current Ratio16.97 Quick Ratio16.97 Sales & Book Value Annual Sales$209.18 million Price / Sales18.48 Cash Flow$4.74 per share Price / Cash Flow13.11 Book Value$11.33 per share Price / Book5.48Miscellaneous Outstanding Shares62,211,000Free Float59,163,000Market Cap$3.87 billion OptionableOptionable Beta2.22 Social Links 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:PTGX) was last updated on 9/19/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protagonist Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Protagonist Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.